ARTELO BIOSCIENCES, INC. (ARTL): Nasdaq/NYSE listing notice — Artelo Biosciences receives Nasdaq delisting notice; plans to appeal

ARTELO BIOSCIENCES, INC.

Received delist determination on Nov 19, 2025 for non-compliance with equity rule (min $2.5M stockholders' equity).
Submitted compliance plans on July 7 and Aug 29, 2025, but did not complete the planned capital raise.
Unless appeal requested by Nov 26, delisting effective Dec 1, 2025; intends to appeal to Nasdaq hearing panel.
Stock (ARTL) continues trading on Nasdaq during appeal process.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ARTELO BIOSCIENCES, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

ndicated that unless the Company requests a hearing panel appeal of the delist determination by November 26, 2025, its securities would be delisted on December 1, 2025. The Company intends to appeal Nasdaq’s determination to a hearing panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series to stay any further delisting actions through the hearing or any extension the hearings panel provides. Following the appeal request, the Company’s common stock, par value $0.001 per share, will continue to trade on Nasdaq under the symbol “ARTL.” 2 SIGNATURES Pursuant to the requir

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ARTELO BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001640334-25-002210

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.